Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 39 results.
User Information
Export Records
  1. 1.   A Dual-Readout F(2) Assay That Combines Fluorescence Resonance Energy Transfer and Fluorescence Polarization for Monitoring Bimolecular Interactions
  2. Du, Y. H.; Nikolovska-Coleska, Z.; Qui, M.; Li, L.; Lewis, I.; Dingledine, R.; Stuckey, J. A.; Krajewski, K.; Roller, P. P.; Wang, S. M.; Fu, H. A.
  3. Assay and Drug Development Technologies. 2011, Aug; 9(4): 382-393.
  1. 2.   Complement Opsonization of HIV-1 Enhances the Uptake by Dendritic Cells and Involves the Endocytic Lectin and Integrin Receptor Families
  2. Tjomsl, V.; Ellegard, R.; Che, K.; Hinkula, J.; Lifson, J. D.; Larsson, M.
  3. Plos One. 2011, Aug; 6(8): 12.
  1. 3.   The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy
  2. Xiang, X. R.; Phung, Y.; Feng, M. Q.; Nagashima, K.; Zhang, J. L.; Broaddus, V. C.; Hassan, R.; FitzGerald, D.; Ho, M.
  3. Plos One. 2011, Jan; 6(1): 10.
  1. 4.   Arsenic-Specific Stem Cell Selection During Malignant Transformation
  2. Tokar, E. J.; Qu, W.; Liu, J.; Liu, W.; Webber, M. M.; Phang, J. M.; Waalkes, M. P.
  3. Journal of the National Cancer Institute. 2010, May; 102(9): 638-649.
  1. 5.   Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax
  2. Garg, H.; Salcedo, R.; Trinchieri, G.; Blumenthal, R.
  3. Cancer Gene Therapy. 2010, Mar; 17(3): 155-163.
  1. 6.   Molecular mediators of macrophage fusion
  2. Helming, L.; Gordon, S.
  3. Trends in Cell Biology. 2009 19(10): 514-522.
  1. 7.   Mitochondrial degeneration and not apoptosis is the primary cause of embryonic lethality in ceramide transfer protein mutant mice
  2. Wang, X.; Rao, R. P.; Kosakowska-Cholody, T.; Masood, M. A.; Southon, E.; Zhang, H. L.; Berthet, C.; Nagashim, K.; Veenstra, T. K.; Tessarollo, L.; Acharya, U.; Acharya, J. K.
  3. Journal of Cell Biology. 2009 184(1): 143-158.
  1. 8.   The nitric oxide prodrug, V-PYRRO/NO, mitigates arsenic-induced liver cell toxicity and apoptosis
  2. Qu, W.; Liu, J.; Fuquay, R.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Cancer Letters. 2007, Oct; 256(2): 238-245.
  1. 9.   Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors
  2. Khan, T.; Stauffer, J. K.; Williams, R.; Hixon, J. A.; Salcedo, R.; Lincoln, E.; Back, T. C.; Powell, D.; Lockett, S.; Arnold, A. C.; Sayers, T. J.; Wigginton, J. M.
  3. Journal of Immunology. 2006, MAY 15; 176(10): 6302-6312.
  1. 10.   Combining proteasome inhibition with TNF-related apoptosis-inducing ligand (Apo2L/TRAIL) for cancer therapy
  2. Sayers, T. J.; Murphy, W. J.
  3. Cancer Immunology Immunotherapy. 2006, JAN; 55(1): 76-84.
  1. 11.   The role of IL-6 and STAT3 in inflammation and cancer
  2. Hodge, D. R.; Hurt, E. M.; Farrar, W. L.
  3. European Journal of Cancer. 2005, NOV; 41(16): 2502-2512.
  1. 12.   Low level, long-term inorganic arsenite exposure causes generalized resistance to apoptosis in cultured human keratinocytes: Potential role in skin co-carcinogenesis
  2. Pi, J. B.; He, Y. Y.; Bortner, C.; Huang, J. L.; Liu, J.; Zhou, T.; Qu, W.; North, S. L.; Kasprzak, K. S.; Diwan, B. A.; Chignell, C. F.; Waalkes, M. P.
  3. International Journal of Cancer. 2005, AUG 10; 116(1): 20-26.
  1. 13.   Cytokine-driven cell cycling is mediated through Cdc25A
  2. Khaled, A. R.; Bulavin, D. V.; Kittipatarin, C.; Li, W. Q.; Alvarez, M.; Kim, K.; Young, H. A.; Fornace, A. J.; Durum, S. K.
  3. Journal of Cell Biology. 2005, JUN 6; 169(5): 755-763.
  1. 14.   Reduction of the antiapoptotic protein cFLIP enhances the susceptibility of human renal cancer cells to TRAIL apoptosis
  2. Brooks, A. D.; Sayers, T. J.
  3. Cancer Immunology Immunotherapy. 2005, MAY; 54(5): 499-505.
  1. 15.   The nitric oxide prodrug, V-PYRRO/NO, protects against cadmium toxicity and apoptosis at the cellular level
  2. Qu, W.; Liu, J.; Fuquay, R.; Shimoda, R.; Sakurai, T.; Saavedra, J. E.; Keefer, L. K.; Waalkes, M. P.
  3. Nitric Oxide-Biology and Chemistry. 2005, MAR; 12(2): 114-120.
  1. 16.   Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines
  2. Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; Piccagli, L.; Baruchello, R.; Rossi, M.; Romagnoli, R.; Invidiata, F. P.; Grimaudo, S.; Jung, M. K.; Hamel, E.; Gebbia, N.; Crosta, L.; Abbadessa, V.; Di Cristina, A.; Dusonchet, L.; Meli, M.; Tolomeo, M.
  3. Journal of Medicinal Chemistry. 2005, FEB 10; 48(3): 723-736.
  1. 17.   Actin-myosin-based contraction is responsible for apoptotic nuclear disintegration
  2. Croft, D. R.; Coleman, M. L.; Li, S. X.; Robertson, D.; Sullivan, T.; Stewart, C. L.; Olson, M. F.
  3. Journal of Cell Biology. 2005, JAN 17; 168(2): 245-255.
  1. 18.   Effect of cell cycle inhibition on cisplatin-induced cytotoxicity
  2. Fishel, M. L.; Newell, D. R.; Griffin, R. J.; Davison, R.; Wang, L. Z.; Curtin, N. J.; Zuhowski, E. G.; Kasza, K.; Egorin, M. J.; Moschel, R. C.; Dolan, M. E.
  3. Journal of Pharmacology and Experimental Therapeutics. 2005, JAN; 312(1): 206-213.
  1. 19.   Induction of apoptosis by flavopiridol in human neuroblastoma cells is enhanced under hypoxia and associated with N-myc proto-oncogene down-regulation
  2. Puppo, M.; Pastorino, S.; Melillo, G.; Pezzolo, A.; Varesio, L.; Bosco, M. C.
  3. Clinical Cancer Research. 2004, DEC 15; 10(24): 8704-8719.
  1. 20.   BCL-x(L)-dependent light scattering by apoptotic cells
  2. Boustany, N. N.; Tsai, Y. C.; Pfister, B.; Joiner, W. M.; Oyler, G. A.; Thakor, N. V.
  3. Biophysical Journal. 2004, DEC; 87(6): 4163-4171.
  1. 21.   Caspase-mediated apoptosis and caspase-independent cell death induced by irofulven in prostate cancer cells
  2. Liang, H. Y.; Salinas, R. A.; Leal, B. Z.; Kosakowska-Cholody, T.; Michejda, C. J.; Waters, S. J.; Herman, T. S.; Woynarowski, J. M.; Woynarowska, B. A.
  3. Molecular Cancer Therapeutics. 2004, NOV; 3(11): 1385-1396.
  1. 22.   Components of the cell death machine and drug sensitivity of the National Cancer Institute cell line panel
  2. Svingen, P. A.; Loegering, D.; Rodriquez, J.; Meng, X. W.; Mesner, P. W.; Holbeck, S.; Monks, A.; Krajewski, S.; Scudiero, D. A.; Sausville, E. A.; Reed, J. C.; Lazebnik, Y. A.; Kaufmann, S. H.
  3. Clinical Cancer Research. 2004, OCT 15; 10(20): 6807-6820.
  1. 23.   Nitric oxide, a mediator of inflammation, suppresses tumorigenesis
  2. Hussain, S. P.; Trivers, G. E.; Hofseth, L. J.; He, P. J.; Shaikh, I.; Mechanic, L. E.; Doja, S.; Jiang, W. D.; Subleski, J.; Shorts, L.; Haines, D.; Laubach, V. E.; Wiltrout, R. H.; Djurickovic, D.; Harris, C. C.
  3. Cancer Research. 2004, OCT 1; 64(19): 6849-6853.
  1. 24.   Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1
  2. Ramakrishnan, R.; Fujimura, Y.; Zou, J. P.; Liu, F.; Lee, L.; Rao, V. N.; Reddy, E. S. P.
  3. Oncogene. 2004, SEP 16; 23(42): 7087-7094.
  1. 25.   Functional characterization of the candidate tumor suppressor gene NPRL2/G21 located in 3p21.3C
  2. Li, F.; Wang, F.; Haraldson, K.; Protopopov, A.; Duh, F. M.; Geil, L.; Kuzmin, I.; Minna, J. D.; Stanbridge, E.; Braga, E.; Kashuba, V. I.; Klein, G.; Lerman, M. I.; Zabarovsky, E. R.
  3. Cancer Research. 2004, SEP 15; 64(18): 6438-6443.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel